TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3894216

Group type: EXPERIMENTAL
Intervention: Butoconazole nitrate cream (3-day course)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Miconazole nitrate cream (7-day course)
Number of subjects: 100
Study: 30725428

Group type: EXPERIMENTAL
Intervention: WLS Forte®
Number of subjects: 148

Group type: COMPARATOR
Intervention: sMVS
Number of subjects: 148
Study: 29643323

Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg once daily)
Number of subjects: 355

Group type: COMPARATOR
Intervention: voglibose (0.2 mg/meal thrice daily)
Number of subjects: 355
Study: 28699565

Group type: EXPERIMENTAL
Intervention: Community mobilisation for dengue prevention (intervention clusters)
Number of subjects: 12312

Group type: COMPARATOR
Intervention: Control (control clusters)
Number of subjects: 12312
Study: 25316485

Group type: EXPERIMENTAL
Intervention: Sentinel node based management (SNBM)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Routine axillary clearance (RAC)
Number of subjects: 1088
Study: 22891893

Group type: EXPERIMENTAL
Intervention: IGIV‐C (immune globulin intravenously)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: IGIV‐C
Number of subjects: 117
Study: 21397284

Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil (15 g/d TFA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control oil (mainly oleic and palmitic acid)
Number of subjects: 52
Study: 18270137

Group type: EXPERIMENTAL
Intervention: Active filling of the left atrium by a line from the aortic cannula and venting from the antegrade cardioplegia line (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ventilating the lungs and venting from the antegrade cardioplegia line without active filling of the left atrium (Group 2)
Number of subjects: 40
Study: 16194527

Group type: EXPERIMENTAL
Intervention: Visual cue presented in corresponding anatomical location on a model's body
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual cue presented on a non-body control stimulus
Number of subjects: 0
Study: 12974687

Group type: EXPERIMENTAL
Intervention: Groups A-D (brushed after different times post-erosion: A - immediately, B - 20 min, C - 40 min, D - 60 min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group E (only acid-eroded)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group F (only brushed)
Number of subjects: 120
Study: 10719945

Group type: EXPERIMENTAL
Intervention: Aprotinin (n = 40)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined therapy (tranexamic acid with autologous blood collection, n = 32)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo group (saline infusion, n = 43)
Number of subjects: 160
Study: 9267667

Group type: EXPERIMENTAL
Intervention: T-cell depleted marrow grafts
Number of subjects: 92

Group type: COMPARATOR
Intervention: Unmodified marrow grafts
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both DR beta 1 and DQ beta matching
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Receiving a T-cell depleted graft
Number of subjects: 92
Study: 7504977

Group type: EXPERIMENTAL
Intervention: Low doses of aprotinin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical doses of aprotinin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dosed aprotinin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical and reduced aprotinin dosages
Number of subjects: 60
Study: 3797115

Group type: EXPERIMENTAL
Intervention: Natural human surfactant (60 mg surfactant/kg body weight)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Natural human surfactant
Number of subjects: 29
Study: 28870494

Group type: EXPERIMENTAL
Intervention: Telehealth care coordination intervention delivered by advanced practice registered nurses
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Baseline HRQL and presence of neurologic impairment and technology dependence
Number of subjects: 163
Study: 27737646

Group type: EXPERIMENTAL
Intervention: 4200 IU/week vitamin D supplementation from 2nd trimester to delivery plus placebo from 0-6 months postpartum
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 16800 IU/week vitamin D supplementation from 2nd trimester to delivery plus placebo from 0-6 months postpartum
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 28000 IU/week vitamin D supplementation from 2nd trimester to delivery plus placebo from 0-6 months postpartum
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 28000 IU/week prenatal and until 6 months postpartum
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study: 24219822

Group type: EXPERIMENTAL
Intervention: HDWLE + eCLE + TB
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: In vivo CLE
Number of subjects: 192

Group type: COMPARATOR
Intervention: HDWLE + RB
Number of subjects: 192
Study: 23551243

Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 supplementation (2000 IU per day for 30 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated summer UV exposure (10 sunbed sessions to a total dose of 23.8 SED)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both interventions (oral vitamin D3 and UV exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-body sunbed exposure (4.8 SED twice weekly)
Number of subjects: 0
Study: 19501354

Group type: EXPERIMENTAL
Intervention: 0.1 mg triptorelin (group A; n=172)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Solvent only (group B; n=172)
Number of subjects: 344
Study: 18978272

Group type: EXPERIMENTAL
Intervention: Three-dimensional (3D) reconstruction plate
Number of subjects: 133

Group type: COMPARATOR
Intervention: Superior plate
Number of subjects: 133
Study: 16681719

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1 and 8, sequence T‐‐>G
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m(2) and paclitaxel 150 mg/m(2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) and paclitaxel 175 mg/m(2) with sequence G‐‐>T
Number of subjects: 39
Study: 12809965

Group type: EXPERIMENTAL
Intervention: Statin use (1892 patients, 21.9% of total); mean TC level of 5.99 mmol/L (231.6 mg/dL) at end of study; 1096 patients (57.9%) had TC levels above cutoff.
Number of subjects: 8653

Group type: COMPARATOR
Intervention: No statin use (6761 patients, 78.1% of total); mean TC level of 6.24 mmol/L (241.4 mg/dL) at end of study; 5316 patients (78.6%) had TC levels above cutoff.
Number of subjects: 8653
Study: 11182393

Group type: EXPERIMENTAL
Intervention: Subareolar injection of technetium‐99 sulfur colloid and blue dye
Number of subjects: 38

Group type: COMPARATOR
Intervention: Peritumoral injection of technetium‐99 sulfur colloid and blue dye
Number of subjects: 38
Study: 7641751

Group type: EXPERIMENTAL
Intervention: Technetium-99m HMPAO SPET
Number of subjects: 27

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 27
Study: 2496149

Group type: COMPARATOR
Intervention: Fluvoxamine, 100 mg daily for 17 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clovoxamine, 150 mg daily for 17 days
Number of subjects: 0
Study: 323023

Group type: EXPERIMENTAL
Intervention: Tolamolol (300 mg/day - 900 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methyldopa (750 mg/day - 2250 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Methyldopa (Control)
Number of subjects: 13
Study: 31880827

Group type: EXPERIMENTAL
Intervention: Low-fat adaptation condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat adaptation condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-muscle adaptation condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-muscle adaptation condition
Number of subjects: 0
Study: 31711300

Group type: EXPERIMENTAL
Intervention: Household water quality self-testing and receipt of information (handouts) on improving water quality
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 512
Study: 28290704

Group type: EXPERIMENTAL
Intervention: Ankle-joint mobilization (AJM)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Plantar massage (PM)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Calf stretching (CS)
Number of subjects: 59
Study: 26682608

Group type: EXPERIMENTAL
Intervention: 8-week gross motor skills program (10 min. daily)
Number of subjects: 60
Study: 24135213

Group type: EXPERIMENTAL
Intervention: E‐couch program (unguided Web‐based program based on cognitive behavioral therapy and interpersonal therapy)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: E‐couch program
Number of subjects: 280
Study: 20605477

Group type: EXPERIMENTAL
Intervention: Mandibular nerve block (MNB) with 5 mL ropivacaine 0.5% for each block
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mandibular nerve block (MNB)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham MNB (Control)
Number of subjects: 38
Study: 18348597

Group type: EXPERIMENTAL
Intervention: memantine 20 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: escitalopram 20 mg/day
Number of subjects: 80
Study: 17146409

Group type: EXPERIMENTAL
Intervention: m-CPP 0.5 mg/kg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 14586322

Group type: EXPERIMENTAL
Intervention: Paternal age >= 40 years
Number of subjects: 6188

Group type: COMPARATOR
Intervention: Paternal age < 40 years
Number of subjects: 6188
Study: 11063437

Group type: EXPERIMENTAL
Intervention: High-MUFA diet (20.3 +/- 3.5% of total energy)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-PUFA diet (13.4 +/- 1.3% of total energy)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard test meal (identical for both diets)
Number of subjects: 9
Study: 9057142

Group type: EXPERIMENTAL
Intervention: Intramedullary fixation for femoral shaft fractures
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Closed femoral shortening
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (asymptomatic)
Number of subjects: 46
Study: 7943920

Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam p.o.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3723287

Group type: EXPERIMENTAL
Intervention: AMPS program (alcohol misuse prevention study) consisting of four sessions focusing on immediate effects of alcohol, risks of alcohol misuse, and social pressures to misuse alcohol.
Number of subjects: 5635

Group type: EXPERIMENTAL
Intervention: AMPS program (alcohol misuse prevention study)
Number of subjects: 5635

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5635
Study: 31577449

Group type: EXPERIMENTAL
Intervention: PainCheck e-health tool for pain management
Number of subjects: 0
Study: 29988111

Group type: EXPERIMENTAL
Intervention: Catumaxomab followed by chemotherapy (FLOT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: FLOT alone
Number of subjects: 31
Study: 26813241

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 194
Study: 25188566

Group type: EXPERIMENTAL
Intervention: Dynamic interpersonal group psychotherapy (DIGP), 16 sessions held weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22551950

Group type: EXPERIMENTAL
Intervention: Low-fat high-complex carbohydrate diets (LFHCC)
Number of subjects: 42
Study: 19725896

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study: 18607743

Group type: EXPERIMENTAL
Intervention: Proprioceptive correction costume
Number of subjects: 23
Study: 16029682

Group type: EXPERIMENTAL
Intervention: 1% 4-ethoxybenzaldehyde
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30
Study: 11814530

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 10521742

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous labetalol (20 mg)
Number of subjects: 50
Study: 8928194

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (topical nasal drop of 0.1% betamethasone for 12 patients and oral administration of prednisolone for 5 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study: 1505264

Group type: EXPERIMENTAL
Intervention: Easy-Flow drain
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 80
Study: 6388588

Group type: EXPERIMENTAL
Intervention: 50 g glucose load with 50 g ethanol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Starch solution (maize meal) and alcohol
Number of subjects: 14
Study: 30678670

Group type: EXPERIMENTAL
Intervention: Telehealth intervention group (CyFiT OPS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual Outpatient Physiotherapy Service group (Usual OPS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (CyFiT OPS and Usual OPS)
Number of subjects: 110
Study: 29138226

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24989993

Group type: EXPERIMENTAL
Intervention: Rosetta system
Number of subjects: 0
Study: 25060690

Group type: EXPERIMENTAL
Intervention: Low-dose ethanol intervention
Number of subjects: 39
Study: 22235808

Group type: EXPERIMENTAL
Intervention: Standard care plus 12 weekly music therapy sessions delivered by the Northern Ireland Music Therapy Trust
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200
Study: 20929718

Group type: EXPERIMENTAL
Intervention: Ultra-mild self-etch adhesive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lab-SiC-prepared surface
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bur-prepared surface
Number of subjects: 0
Study: 18598321

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 10

Group type: COMPARATOR
Intervention: LV pacing
Number of subjects: 10
Study: 15947764

Group type: EXPERIMENTAL
Intervention: Pulsed wave Doppler tissue imaging
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: E/Em ratio greater than 9
Number of subjects: 87
Study: 11895049

Group type: COMPARATOR
Intervention: Colesevelam and lovastatin coadministered with dinner
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Colesevelam with dinner and lovastatin 4 hours later with a snack
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lovastatin alone administered with dinner
Number of subjects: 22
Study: 10516540

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8544722

Group type: EXPERIMENTAL
Intervention: CFM (480 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: RM (480 ml)
Number of subjects: 30
Study: 1952848

Group type: EXPERIMENTAL
Intervention: Cefazolin (n = 63)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Cefoxitin (n = 66)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Cefotaxime (n = 60)
Number of subjects: 194
Study: 7002830

Group type: EXPERIMENTAL
Intervention: 60 mg Mianserin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 90 mg Mianserin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 120 mg Mianserin
Number of subjects: 12
Study: 31291786

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study: 28369971

Group type: EXPERIMENTAL
Intervention: Mirasol-treated RBCs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated RBCs (Control)
Number of subjects: 24
Study: 26014129

Group type: EXPERIMENTAL
Intervention: BCG and mitomycin
Number of subjects: 500

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 500
Study: 24359456

Group type: EXPERIMENTAL
Intervention: COSTRIDE intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: HW intervention (control)
Number of subjects: 219
Study: 22722961

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 20
Study: 19786805

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy children (control)
Number of subjects: 66
Study: 17442226

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal angioplasty (PTRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing trials
Number of subjects: 0
Study: 16332656

Group type: EXPERIMENTAL
Intervention: rhGH + IDPN + exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: IDPN + exercise
Number of subjects: 7
Study: 12145434

Group type: EXPERIMENTAL
Intervention: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + calcipotriol ointment (50 microg/g), applied twice daily
Number of subjects: 143

Group type: COMPARATOR
Intervention: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + ointment vehicle
Number of subjects: 143
Study: 9689424

Group type: EXPERIMENTAL
Intervention: Reproterol + DSCG by HFA-MDI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reproterol + DSCG by CFC-MDI
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo by HFA-MDI
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo by CFC-MDI
Number of subjects: 24
Study: 7985634

Group type: EXPERIMENTAL
Intervention: Diet M (high in myristic acid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet P (high in palmitic acid)
Number of subjects: 12
Study: 3143482

Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ergotamine tartrate compound
Number of subjects: 61
Study: 29488226

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg Q2W
Number of subjects: 493

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 493
Study: 26850809

Group type: EXPERIMENTAL
Intervention: Yoga intervention (18 sessions, 3 times per week, 1 hour per session)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study: 25594355

Group type: EXPERIMENTAL
Intervention: Emulsion with active substances (hyaluronic acid, sericin, glycerol, urea)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gel with active substances (hyaluronic acid, sericin, glycerol, urea)
Number of subjects: 20
Study: 21945402

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 20819579

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 800
Study: 17310359

Group type: COMPARATOR
Intervention: dDAVP
Number of subjects: 151

Group type: COMPARATOR
Intervention: Homotoxicological remedies
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 16514482

Group type: EXPERIMENTAL
Intervention: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (5, 15, or 25 mcg/m2 on days 1, 8, and 15 starting in the second cycle)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (35 mcg/m2, non-randomized)
Number of subjects: 33
Study: 12966426

Group type: EXPERIMENTAL
Intervention: No HPV
Number of subjects: 93

Group type: COMPARATOR
Intervention: With HPV
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Five or fewer lifetime sexual partners
Number of subjects: 93

Group type: COMPARATOR
Intervention: More than five lifetime sexual partners
Number of subjects: 93
Study: 10481115

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8892674

Group type: EXPERIMENTAL
Intervention: VDJ rearrangements derived by PCR with VH gene family‐specific primers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Analysis of rearrangements in one patient at first bone marrow relapse
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Presence of absent N nucleotides in the DJ border
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sequencing of more than one rearrangement
Number of subjects: 32
Study: 1994537

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6661620

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31642526

Group type: EXPERIMENTAL
Intervention: Applied behavior analytic intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 6
Study: 29426320

Group type: EXPERIMENTAL
Intervention: SPEEDI (Supporting Play Exploration and Early Development Intervention)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 14
Study: 27224642

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 4055

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4055

Group type: EXPERIMENTAL
Intervention: Health-economic analysis of LDCT screening
Number of subjects: 4055
Study: 24293405

Group type: EXPERIMENTAL
Intervention: Simplified visual quantitative score (SQS) of late gadolinium enhancement (LGE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Initial hospitalization characteristics
Number of subjects: 28
Study: 22173570

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.1 μg/kg/min for 10 min loading dose, followed by 0.4 μg/kg/h continuous infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Propofol 0.1 mg/kg/min for 10 min loading dose, followed by 1 mg/kg/h continuous infusion
Number of subjects: 32